MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
Boston Scientific Corporation Operating Income 2011-2026 | BSX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Boston Scientific Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.61 B | 2.6 B | 2.34 B | 1.65 B | 1.2 B | -80 M | 1.52 B | 1.51 B | 1.28 B | 447 M | -283 M | -301 M | 120 M | -3.87 B | 904 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.61 B | -3.87 B | 844 M |
Quarterly Operating Income Boston Scientific Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.05 B | 819 M | 921 M | 733 M | 520 M | 675 M | 693 M | 514 M | 552 M | - | 358 M | 423 M | 466 M | - | 387 M | 262 M | 370 M | - | -205 M | -71 M | 146 M | - | 383 M | 384 M | 541 M | - | 388 M | 392 M | 407 M | - | 377 M | 225 M | 364 M | - | 348 M | -334 M | 293 M | - | -299 M | 219 M | 24 M | - | 64 M | -69 M | 197 M | - | 103 M | 220 M | -330 M | - | -594 M | -3.59 B | 196 M | - | 174 M | 237 M | 322 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 B | -3.59 B | 206 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 8.99 | -4.16 % | $ 255 M |  USA |
 |
EDAP TMS S.A.
EDAP
|
-19.8 M | $ 3.45 | -0.29 % | $ 129 M |  France |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 12.01 | -0.5 % | $ 1.62 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.6 | - | $ 122 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 36.14 | -1.65 % | $ 5.38 K | USA |
 |
Globus Medical
GMED
|
480 M | $ 90.07 | 1.66 % | $ 12.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 1.78 | -6.32 % | $ 1.08 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 9.27 | -0.43 % | $ 714 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 54.06 | -0.15 % | $ 1.59 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.01 | 1.34 % | $ 17.1 M | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 85.48 | -0.18 % | $ 2.97 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.68 | -1.63 % | $ 368 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.83 | -1.1 % | $ 69.7 M | USA |
 |
Medtronic PLC
MDT
|
5.96 B | $ 86.15 | -0.15 % | $ 111 B | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.66 | -5.68 % | $ 27.6 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
Align Technology
ALGN
|
608 M | $ 166.53 | -3.11 % | $ 12.5 B | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.68 | -0.76 % | $ 463 M |  Curacao |
 |
AxoGen
AXGN
|
-7.85 M | $ 30.86 | -5.45 % | $ 1.42 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Penumbra
PEN
|
189 M | $ 329.86 | - | $ 12.8 B | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 202.45 | -0.52 % | $ 14.2 B | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.53 | - | $ 7.02 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 4.03 | -2.54 % | $ 853 M | USA |
 |
Smith & Nephew plc
SNN
|
593 M | $ 31.63 | -3.06 % | $ 23.8 B |  Britain |
 |
Stryker Corporation
SYK
|
4.89 B | $ 330.34 | -0.59 % | $ 126 B | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.59 | 0.76 % | $ 36.7 M | USA |
 |
Tactile Systems Technology
TCMD
|
29.3 M | $ 24.31 | -1.06 % | $ 556 M | USA |
 |
TELA Bio
TELA
|
-33.8 M | $ 0.67 | 6.38 % | $ 31.5 M | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 106.65 | 1.77 % | $ 3.63 B | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Tandem Diabetes Care
TNDM
|
8.29 M | $ 19.31 | 0.74 % | $ 1.31 B | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 9.64 | -0.67 % | $ 345 M | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |